Takeda And Nanotherapeutics Announce Agreement To Expand Takeda's Commercialization And Technology Access Rights In Support Of Influenza And Other Vaccine Programs

ALACHUA, Fla. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (Takeda) (TOKYO: 4502) and Nanotherapeutics, Inc., announced an agreement providing Takeda with expanded commercialization and technology access rights related to Nanotherapeutics’ Vero cell technology platform – a cell culture-based platform for vaccine production which Nanotherapeutics acquired from Baxalta, formerly Baxter International’s BioScience division. Financial terms of the agreement were not disclosed.

Help employers find you! Check out all the jobs and post your resume.